JP2008545145A5 - - Google Patents

Download PDF

Info

Publication number
JP2008545145A5
JP2008545145A5 JP2008519853A JP2008519853A JP2008545145A5 JP 2008545145 A5 JP2008545145 A5 JP 2008545145A5 JP 2008519853 A JP2008519853 A JP 2008519853A JP 2008519853 A JP2008519853 A JP 2008519853A JP 2008545145 A5 JP2008545145 A5 JP 2008545145A5
Authority
JP
Japan
Prior art keywords
antibody
therapeutic
therapeutic antibody
target antigen
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008519853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545145A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/006524 external-priority patent/WO2007003420A1/en
Publication of JP2008545145A publication Critical patent/JP2008545145A/ja
Publication of JP2008545145A5 publication Critical patent/JP2008545145A5/ja
Pending legal-status Critical Current

Links

JP2008519853A 2005-07-06 2006-07-05 対応治療抗体の有無を問わない標的抗原の検出 Pending JP2008545145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06
PCT/EP2006/006524 WO2007003420A1 (en) 2005-07-06 2006-07-05 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Publications (2)

Publication Number Publication Date
JP2008545145A JP2008545145A (ja) 2008-12-11
JP2008545145A5 true JP2008545145A5 (enExample) 2010-11-18

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008519853A Pending JP2008545145A (ja) 2005-07-06 2006-07-05 対応治療抗体の有無を問わない標的抗原の検出

Country Status (19)

Country Link
US (1) US20070009976A1 (enExample)
EP (2) EP2194380A3 (enExample)
JP (1) JP2008545145A (enExample)
KR (1) KR20080016939A (enExample)
AR (1) AR053948A1 (enExample)
AU (1) AU2006265275A1 (enExample)
BR (1) BRPI0612591A2 (enExample)
CA (1) CA2613187A1 (enExample)
CR (1) CR9635A (enExample)
EC (1) ECSP088081A (enExample)
IL (1) IL188317A0 (enExample)
MA (1) MA29730B1 (enExample)
MX (1) MX2008000277A (enExample)
MY (1) MY157955A (enExample)
NO (1) NO20076662L (enExample)
NZ (1) NZ564471A (enExample)
RU (1) RU2008103608A (enExample)
TW (1) TWI312864B (enExample)
WO (1) WO2007003420A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522444A (en) * 2000-05-19 2004-09-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
SI1771482T1 (sl) * 2004-07-22 2014-12-31 Genentech, Inc. Sestavek HER2 protitelesa
WO2007092545A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Variable imaging arrangements and methods therefor
KR101134208B1 (ko) 2004-10-01 2012-04-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 촬상 장치 및 그 방법
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
NZ590431A (en) 2005-02-23 2012-08-31 Genentech Inc Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
CN101680897B (zh) 2007-03-02 2013-11-13 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MX2014004021A (es) 2011-10-14 2014-04-30 Genentech Inc Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab.
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
RU2737727C2 (ru) 2013-04-16 2020-12-02 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
SG11201608912VA (en) 2014-04-25 2016-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
RS65871B1 (sr) 2015-05-30 2024-09-30 Hoffmann La Roche Postupci lečenja her2-pozitivnog prethodno nelečenog metastatskog karcinoma dojke
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20180221481A1 (en) 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
TWI729259B (zh) 2017-01-17 2021-06-01 美商建南德克公司 皮下her2 抗體調配物
CN114984206A (zh) 2017-03-02 2022-09-02 基因泰克公司 Her2阳性乳腺癌的辅助治疗
TW201902509A (zh) 2017-04-24 2019-01-16 美商建南德克公司 Erbb2/her2突變
KR20230030621A (ko) 2020-06-29 2023-03-06 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
IL129354A0 (en) 1996-10-18 2000-02-17 Genentech Inc Anti-ErbB2 antibodies
EP2131198B1 (en) * 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
PT2263691E (pt) * 2002-07-15 2012-11-12 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)

Similar Documents

Publication Publication Date Title
JP2008545145A5 (enExample)
HRP20191341T1 (hr) Protutijela koja vežu ljudski cgrp receptor
JP2020522261A5 (enExample)
JP2013506675A5 (enExample)
JP2019523651A5 (enExample)
RU2008103608A (ru) Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела
WO2003074566A3 (en) Rs7 antibodies
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
RU2018131622A (ru) Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis
JP2013506428A5 (enExample)
JP2016500251A5 (enExample)
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
JP2014526898A5 (enExample)
JP2011184466A5 (enExample)
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
JP2013538057A5 (enExample)
JP2005529587A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2011509079A5 (enExample)
JP2018504610A5 (enExample)
IL212056A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
RU2011139083A (ru) АНТИ-CεmX АНТИТЕЛА, СПОСОБНЫЕ СВЯЗЫВАТЬСЯ С mIgE ЧЕЛОВЕКА В ЛИМФОЦИТАХ
JP2021500916A5 (enExample)
JP2016509585A5 (enExample)
JP2019520034A5 (enExample)